Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Selvaggi

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
JTO Clinical and Research Reports|May 21, 2026
Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914]Surbhi Singhal, Caressa Hui, Joel W Neal, et al.
Cancers|May 26, 2018
A Phase II Study of Pelareorep (REOLYSIN<sup>®</sup>) in Combination with Gemcitabine for Patients with Advanced Pancreatic AdenocarcinomaDevalingam Mahalingam, Sanjay Goel, Santiago Aparo, et al.
Cancer Letters|March 22, 2023
Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancerYang Xia, Rui Jin, Miao Li, et al.
Cancer|December 29, 2015
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumorsMiguel A Villalona-Calero, Elaine Lam, Gregory A Otterson, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2022
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumorsNusayba A Bagegni, Haeseong Park, Katlyn Kraft, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trialGiorgio V Scagliotti, Cornelius Kortsik, Graham G Dark, et al.
Cancer|July 2, 2003
Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational StudyFederico Cappuzzo, Giovanni Selvaggi, Vanesa Gregorc, et al.
JTO Clinical and Research Reports|February 8, 2024
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic TumorsKathryn E Beckermann, Christine M Bestvina, Badi El Osta, et al.
Cancer Cell|May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerMatthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 22, 2019
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B StudyEnriqueta Felip, Filippo G de Braud, Michela Maur, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
JTO Clinical and Research Reports|May 21, 2026
Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914]Surbhi Singhal, Caressa Hui, Joel W Neal, et al.
Cancers|May 26, 2018
A Phase II Study of Pelareorep (REOLYSIN<sup>®</sup>) in Combination with Gemcitabine for Patients with Advanced Pancreatic AdenocarcinomaDevalingam Mahalingam, Sanjay Goel, Santiago Aparo, et al.
Cancer Letters|March 22, 2023
Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancerYang Xia, Rui Jin, Miao Li, et al.
Cancer|December 29, 2015
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumorsMiguel A Villalona-Calero, Elaine Lam, Gregory A Otterson, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2022
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumorsNusayba A Bagegni, Haeseong Park, Katlyn Kraft, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trialGiorgio V Scagliotti, Cornelius Kortsik, Graham G Dark, et al.
Cancer|July 2, 2003
Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational StudyFederico Cappuzzo, Giovanni Selvaggi, Vanesa Gregorc, et al.
JTO Clinical and Research Reports|February 8, 2024
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic TumorsKathryn E Beckermann, Christine M Bestvina, Badi El Osta, et al.
Cancer Cell|May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerMatthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 22, 2019
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B StudyEnriqueta Felip, Filippo G de Braud, Michela Maur, et al.
Pageof 4